Linus Biotechnology is a patient-centric, breakthrough science, precision exposome medicine company. Our program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology.
Location: United States, New York, City of New Rochelle
Member count: 11-50
Total raised: $16M
Founded date: 2020
Funding Rounds 1
Date | Series | Amount | Investors | Deal News |
13.01.2023 | Series A | $16M | - | finsmes.co... |
Mentions in press and media 4
Date | Title | Description | Category | Author | Source |
13.01.2023 | LinusBio R... | LinusBio, a New York-based com... | USA | - | finsmes.co... |
07.12.2021 | Linus Biot... | NEW YORK, Dec. 7, 2021 /PRNews... | - | - | salamancap... |
17.11.2021 | Mount Sina... | NEW YORK, Nov. 17, 2021 /PRNew... | - | - | salamancap... |
- | Linus Biot... | “Originating from world’s lead... | - | - | fastfounde... |